Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Yamin Shu,1– 4,&ast; Qilin Zhang,5,&ast; Xucheng He,6 Li Chen1– 3 1Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, Peop...

Full description

Bibliographic Details
Main Authors:	Shu Y, Zhang Q, He X, Chen L
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-11-01
Series:	Cancer Management and Research
Subjects:	cost-effectiveness gefitinib nsclc egfr markov model
Online Access:	https://www.dovepress.com/cost-effectiveness-analysis-of-gefitinib-plus-chemotherapy-versus-gefi-peer-reviewed-fulltext-article-CMAR

Similar Items

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
by: Yanjun Huang, et al.
Published: (2018-07-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
by: Wang Bing, et al.
Published: (2017-06-01)

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation
by: Xing-Xing Fan, et al.
Published: (2014-03-01)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01)

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis
by: Zhu Jun, et al.
Published: (2013-01-01)

Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer
by: Pengfei Liu, et al.
Published: (2019-02-01)

Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro
by: Wei WEI, et al.
Published: (2009-01-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations
by: Miaomiao Li, et al.
Published: (2022-06-01)

Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer
by: Moulid Hidayat, et al.
Published: (2019-11-01)

Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
by: Shuang Zhao, et al.
Published: (2021-11-01)

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib  in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01)

Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells
by: Shaojia Wang, et al.
Published: (2021-05-01)

Pyogenic Granuloma in a Patient on Gefitinib
by: António Fernandes Massa, et al.
Published: (2016-06-01)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
by: Xiaomeng Wang, et al.
Published: (2021-07-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
by: Melissa Bersanelli, et al.
Published: (2014-09-01)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression
by: Ren Shengnan, et al.
Published: (2022-11-01)

Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy
by: Chung-Yu Huang, et al.
Published: (2020-01-01)

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
by: Yuta Nio, et al.
Published: (2022-11-01)

Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells
by: Jinjin Shao, et al.
Published: (2024-04-01)

Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer
by: Hsien-Neng Huang, et al.
Published: (2024-01-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)

GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells
by: Wan X, et al.
Published: (2023-11-01)

Individual and Combined Treatments with Methylated Resveratrol Analogue DMU-214 and Gefitinib Inhibit Tongue Cancer Cells Growth via Apoptosis Induction and EGFR Inhibition
by: Malgorzata Jozkowiak, et al.
Published: (2021-06-01)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
by: Diego Enrico, MD, et al.
Published: (2023-02-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
by: Norihiro Kikuchi, et al.
Published: (2003-01-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Mucocutaneous side effects of gefitinib
by: Ruhaila Thekkath, et al.
Published: (2021-01-01)

Gefitinib Results in Robust Host-Directed Immunity Against Salmonella Infection Through Proteo-Metabolomic Reprogramming
by: Srikanth Sadhu, et al.
Published: (2021-03-01)

BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway
by: Huang Jin, et al.
Published: (2019-07-01)